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Albuminuria and renal insufficiency prevalence guides popula- Chronic progressive renal impairment is usually an
tion screening: Results from the NHANES III. asymptomatic condition. Community strategies to re-
Background. A number of screening criteria, applied either duce the incidence of end-stage renal disease (ESRD)at a single point in time or serially, can be used for the purpose
may need to integrate methods of screening and earlierof identifying individuals at risk of end-stage renal disease
intervention. Randomized clinical trials best estimate the(ESRD). This study focused on two such criteria measured
on a single occasion, proteinuria and renal insufficiency, and clinical effectiveness of screening compared with usual
examined their prevalence in a sample representative of the care [1]; however, unlike other diseases [2–3], such trials
adult U.S. non-institutionalized population. Such knowledge
do not exist for ESRD prevention, and may not be imme-guides the utility of population screening to prevent ESRD.
diately forthcoming. Current screening clinical practiceMethods. The prevalence of albuminuria (microalbuminuria
and macroalbuminuria from a random urine albumin-to-creati- guidelines and positional statements are based primarily
nine ratio) and renal insufficiency [glomerular filtration rate on expert opinion, longitudinal studies identifying risk
(GFR) estimated from serum creatinine] was determined in factors for ESRD, and single therapy interventional stud-different age categories in various adult screening groups in
ies, and these guidelines do not quantify the effectivenessthe cross-sectional Third National Health and Nutrition Exami-
of screening [4–9]. An estimate of the clinical effectivenessnation Survey (NHANES III).
Results. A total of 14,622 adult participants were included of screening in the absence of randomized clinical trials
in the analysis. In the general population, 8.3% and 1.0% of is possible [10], and requires knowledge of (a) the inci-
participants demonstrated microalbuminuria and macroalbu- dence of ESRD in individuals who demonstrate certainminuria, respectively. To identify one case of albuminuria, one
screening test results; (b) the prevalence of such individu-would need to screen three persons with diabetes mellitus,
als in target groups to be screened, who at the time ofseven non-diabetic hypertensive persons, or six persons over
the age of 60. When albuminuria and renal insufficiency were screening are not receiving effective interventions (such
considered together, it was clear that these tests were identi- as angiotensin converting enzyme inhibitors [11–13],
fying different segments of the population; 37% of participants
blood pressure control [14–15], and dietary protein re-with a GFR less than 30 mL/min/1.73 m2 demonstrated no
striction [16]) to reduce their risk for the outcome; andalbuminuria. Non-albuminuric renal insufficiency was most evi-
dent in the ages of 60 to 79; 34% of diabetics, and 63% of (c) the cumulative effectiveness of interventions to re-
non-diabetic hypertensives with a GFR less than 30 mL/min/ duce the incidence of ESRD, in persons who exhibit
1.73 m2 demonstrated no albuminuria. certain screening test results. This report focuses on crite-
Conclusions. Albuminuria is prevalent, and when consid-
ria that identify individuals with a higher lifetime risk ofered together, screening tests of albuminuria and renal insuffi-
ESRD, and the prevalence of such individuals in targetciency measured on a single occasion identify different segments
of the population. The prevalence of albuminuria and renal in- groups to be screened.
sufficiency in populations of interest should be considered, as this A major challenge in identifying individuals at risk of
knowledge has implications for the effectiveness of screening. ESRD remains that the incidence in the general popula-
tion is low. For example, the U.S. incidence of ESRD
in 1997 was 28.7 per 100,000 [17]. Demographic, clinicalKey words: mass health screening, health status indicators, kidney dis-
ease, glomerular filtration rate, proteinuria, diabetes mellitus. and laboratory criteria have been identified which pre-
dict, from assessment on a single occasion, an increasedReceived for publication September 6, 2001
incidence of ESRD. Longitudinal studies have demon-and in revised form November 26, 2001
Accepted for publication January 14, 2002 strated that black race [18], lower income [18], diabetes
[19], hypertension (and higher systolic and diastolic 2002 by the International Society of Nephrology
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blood pressure) [20], hematuria [21], proteinuria (dip- Inclusion criteria for this analysis were an age of 20 years
or more, measured serum creatinine, and determinationstick proteinuria [21]), and an elevated serum creatinine
[21] are all independent risk factors for ESRD in the of urinary albumin and creatinine.
general community. Other variables such as family his-
Measurementstory of kidney disease [22] and non-steroidal anti-
inflammatory use [23, 24] also may be useful for risk Microalbuminuria/macroalbuminuria. Random day-
time spot urine specimens were collected from partici-stratification. To identify individuals with a higher inci-
dence of ESRD by community screening, it may be nec- pants, and no albuminuria testing was performed on
visibly hematuric or hemoglobin dipstick-positive speci-essary to evaluate a number of these criteria simultane-
ously. The combination of an elevated creatinine and mens. Urinary albumin was measured by fluorescent im-
munoassay, and urinary creatinine by the kinetic alkalineproteinuria may be particularly useful in identifying a
group at higher risk of progression [15, 25, 26]. Utilizing picrate (modified Jaffe´, Autoanalyzer) method. A uri-
nary albumin-to-creatinine ratio (mg/mmol) was calcu-these measurements in target groups delineated by older
age, diabetes and hypertension improves the probability lated. In non-insulin dependent diabetics, a random
urine albumin-to-creatinine ratio between 3.0 and 37.8of finding abnormalities with screening, and improves
the efficacy of screening [10]. mg/mmol (26.8 mg/g to 334.3 mg/g) has been shown to
be over 88% sensitive (SN) and specific (SP) for theThe purpose of the following report was to describe (1)
the prevalence of albuminuria (microalbuminuria and presence of microalbuminuria [albumin excretion rate
of 20 to 200 g/min (28.8 to 288 mg/day) on 24 hourmacroalbuminuria), (2) the relationship between albumin-
uria and elevated serum creatinine, and (3) the number urine] [31]. Similarly a ratio greater than 37.8 mg/mmol
(334.3 mg/g) has been shown to be over 90% SN and SPneeded to screen to identify one person with albuminuria
and/or elevated serum creatinine, in target groups deline- for the presence of macroalbuminuria [albumin excretion
rate greater than 200 g/min (288 mg/day) on 24 hourated by age, diabetes, and hypertension in a community
sample representative of the U.S. adult non-institutional- urine]. In this article, the term ‘albuminuria’ is used to
describe the presence of either microalbuminuria or mac-ized population.
roalbuminuria.
Renal insufficiency. Based on serum creatinine, parti-
METHODS
cipants were grouped into three strata of renal function
Study design, setting and participants [glomerular filtration rate (GFR) 60, 30 to 60 and 30
mL/min/1.73 m2], using cut-off points that have beenThe U.S. Third National Health and Nutrition Exami-
nation Survey (NHANES III) was used to estimate previously validated against inulin clearance [32]. In men
serum creatinine cut points of 137 mol/L (1.5 mg/dL;the prevalence of albuminuria and renal insufficiency in
the community. As of December 2001, previous renal 90% SN, 93% SP, for GFR 60 mL/min/1.73 m2) and
177 mol/L (2.0 mg/dL; 98% SN, 91% SP, for GFR 30reports have examined the prevalence of elevated creati-
nine levels [27], the prevalence of an elevated blood mL/min/1.73 m2) were used. For women serum creatinine
cut points of 104 mol/L (1.2 mg/dL; 88% SN, 90% SP,pressure with renal insufficiency [28], the prevalence and
determinants of childhood albuminuria [29], and the prev- for GFR 60 mL/min/1.73 m2) and 146 mol/L (1.6
mg/dL; 98% SN, 95% SP, for GFR30 mL/min/1.73 m2)alence and association between renal insufficiency and
older adult malnutrition [30] in this dataset. NHANES were used.
Diabetes mellitus/hypertension. Diabetes mellitus (DM)III, sponsored by the U.S. National Center for Health
Statistics, was a cross-sectional survey conducted from was defined as a positive response to the question, “Have
you ever been told by a doctor that you have diabetes or1988 to 1994. The survey utilized a nationwide, stratified,
four stage, area probability sample representative of the sugar diabetes?” Non-diabetic hypertensives were iden-
tified as individuals with a mean systolic blood pressureU.S. civilian non-institutionalized population. The data
from this survey are available in the public domain, and 140 mm Hg, a mean diastolic blood pressure90 mm Hg
diastolic, and/or the current use of antihypertensives [8]provided the opportunity for the independent analysis
reported here. Non-Hispanic blacks, Mexican-Ameri- in the absence of a history of diabetes. Mean blood pres-
sures were based on a total of six measurements taken oncans and the elderly were oversampled in the survey to
improve accuracy in subgroup estimation. Data collec- two separate occasions. Non-diabetic non-hypertensives
were defined by an absence of diabetes and hypertension.tion for the survey occurred in two steps. A standardized
health interview was conducted in the home, and within
Data analysisthe subsequent four weeks a standardized medical exam-
ination and a series of laboratory tests were conducted, The survey data were analyzed using methodology
that accounts for the complex sampling design, usingeither in a mobile examination center, or in the home
of those participants who were unable to visit the center. analytic methods recommended by the U.S. National
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Table 1. Characteristics of survey participants (%)Center for Health Statistics. Sample weights were used
Women 52.0 (0.47)to calculate prevalence estimates and to account for
Age yearsoversampling and nonresponse to the household inter-
20–39 45.9 (1.01)
view and physical examination. Only 1.1% of un- 40–59 32.6 (0.58)
60–79 18.8 (0.81)weighted data were missing due to incomplete diabetes
80 and over 2.7 (0.76)or hypertension assessment. All analyses were conducted
Race
with WesVarPC [33, 34] (Fay’s replication method), a Non-Hispanic white 80.0 (0.72)
Non-Hispanic black 10.9 (0.12)statistical program appropriate for the analysis of com-
Mexican American 5.0 (0.11)plex sample survey data [35]. Weighted chi-squared tests Diabetes 5.2 (0.23)
or two-tailed t tests were used to examine differences Hypertensive
Diabetic 3.1 (0.19)between two proportions or means, and P values of less
Non-diabetic 28.2 (0.89)than 0.05 were considered significant without adjustment Serum creatinine lmol/L
for multiple comparisons. Box-plots and Venn diagrams 177 in men, 146 in women
(GFR 30) 0.6 (0.08)were graphed in Microsoft Excel. On occasion, preva-
137–177 in men, 104–146 in women
lence data is reported as the number of persons “needed- (GFR 30–60) 5.7 (0.41)
137 in men, 104 in womento-be-screened” to identify one patient demonstrating
(GFR 60) 93.7 (0.46)test findings of interest. This value was calculated by
Data are reported as percentage (standard error). Weighted analysis of 14,622dividing 1 by the prevalence of the finding of interest,
adults. GFR, glomerular filtration rate in mL/min/1.73 m2.
in the target group screened. For estimates of prevalence,
point estimates are presented with 95% confidence inter-
vals (CI) in parentheses. The primary analysis utilized
Prevalence of albuminuriavariable measurements as defined above. In supplemen-
tary analyses two other methods of estimating creatinine The prevalence of albuminuria by age, in all partici-
clearance [36] or GFR [37] were substituted for the pre- pants, diabetics, non-diabetic hypertensives, and non-dia-
sented method of GFR assessment. The primary esti- betic non-hypertensives is shown in Table 2. Box-plots of
mates presented in the results were consistent when urine albumin-to-creatinine ratio in all participants by age
other methods of GFR were used (data not shown but are shown in Figure 1. The graphs demonstrate that statis-
available from authors upon request). Supplementary tically, population albuminuria is a positively skewed vari-
analyses used another method of defining the presence able. The cut-off points used to define microalbuminuria,
of albuminuria, a lower gender-specific cut-off values of which have been historically derived on a statistical level
urine albumin to creatinine ratio (men 1.9 mg/mmol, of normal (based on 95 percentiles in reference popula-
women 2.8 mg/mmol) [38]. As expected, there were small tions), are somewhat arbitrary. With this limitation in
increases in the prevalence of albuminuria, and the over- mind, one-third (34.2%) of diabetics demonstrated al-
lap between albuminuria and renal insufficiency, com- buminuria (microalbuminuria 28.1%, macroalbuminuria
pared with presented results. However, overall the re- 6.1%), 14.5% of non-diabetic hypertensives demonstrated
sults were not appreciably different from the presented albuminuria (microalbuminuria 12.8%, macroalbuminuria
1.7%), and 5.1% of non-diabetic non-hypertensives dem-results (data not shown but available from authors upon
onstrated albuminuria (microalbuminuria 4.8%, macro-request).
albuminuria 0.3%). The prevalence of albuminuria was
higher in older participants; 19.1% of participants 60 years
RESULTS of age and older demonstrated albuminuria (16.8% mi-
Demographic information was collected for all persons croalbuminuria, 2.3% macroalbuminuria), and 32.7% of
20 years and over invited to participate in NHANES III octogenarians demonstrated albuminuria (28.0% micro-
(N  23,258), and of these 81% were interviewed (N  albuminuria, 4.7% macroalbuminuria).
18,825), 73% were examined (N  17,030), and 67%
Relationship between albuminuria and(N 14,622) fulfilled the inclusion criteria for this study.
renal insufficiencyReasons for nonresponse were multifactorial. Partici-
pants excluded from the analysis were more likely to be The prevalence of albuminuria and renal insufficiency
older, and to be of non-white racial background (data in all participants, diabetic participants, non-diabetic hy-
not shown). Characteristics for included participants are pertensive participants and non-diabetic non-hyperten-
shown in Table 1. There were 1192 diabetic participants, sive participants, and the relationships between these
4686 non-diabetic hypertensive participants, and 8585 two tests are shown in Table 3, and is depicted graphically
non-diabetic non-hypertensive participants included in as Venn diagrams in Figure 2. In each risk stratum (all
participants, diabetic participants, non-diabetic hyper-the sample.
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Table 2. Prevalence of microalbuminuria and macroalbuminuria in four study groups by age (in decades)
20–29 30–39 40–49 50–59 60–69 70–79 80 Total 95% CI
Whole population
Number 3071 2928 2330 1680 2078 1524 1011 14622
Microalbuminuria 5.4% 5.0% 5.1% 9.6% 12.9% 18.9% 28.0% 8.3% 7.6–9.0%
Macroalbuminuria 0.3% 0.5% 0.8% 1.1% 1.7% 2.3% 4.7% 1.0% 0.8–1.2%
Albuminuria 5.7% 5.5% 5.9% 10.7% 14.6% 21.2% 32.7% 9.2% 8.4–10.0%
Diabetic population
Number 47 91 149 194 325 257 129 1192
Microalbuminuria 13.1% 22.9% 24.6% 22.9% 32.2% 35.8% 36.1% 28.1% 24.5–31.6%
Macroalbuminuria 1.3% 4.6% 7.4% 5.3% 5.4% 6.8% 12.5% 6.1% 3.8–8.4%
Albuminuria 14.4% 27.5% 32.0% 28.2% 37.6% 42.6% 48.6% 34.2% 30.2–38.1%
Non-diabetic hypertensive population
Number 329 536 661 645 1033 841 641 4686
Microalbuminuria 5.4% 4.7% 6.8% 13.6% 14.9% 20.8% 31.1% 12.8% 11.5–14.2%
Macroalbuminuria 0.7% 0.9% 1.7% 1.5% 1.7% 1.8% 4.8% 1.7% 1.2–2.1%
Albuminuria 6.2% 5.5% 8.4% 15.2% 16.5% 22.6% 35.9% 14.5% 13.0–16.0%
Non-diabetic non-hypertensive population
Number 2621 2272 1503 829 710 417 233 8585
Microalbuminuria 5.3% 4.6% 3.5% 4.8% 4.7% 7.5% 14.9% 4.8% 4.3–5.3%
Macroalbuminuria 0.2% 0.3% 0.1% 0.2% 0.7% 1.2% 0.5% 0.3% 0.1–0.5%
Albuminuria 5.6% 4.9% 3.6% 5.1% 5.4% 8.7% 15.5% 5.1% 4.6–5.6%
Albuminuria describes the presence of either microalbuminuria or macroalbuminuria. To convert albumin/creatinine from mg/mmol to mg/g, multiply by 8.84.
The number of participants refers to the crude, unweighted number. The cut-off point used to define microalbuminuria was greater than 3.0 mg/mmol and for
macroalbuminuria was greater than 37.8 mg/mmol.
Fig. 1. Box-plots of random urine albumin-to-
creatinine ratio for all participants. Weighted
analysis of 14,622 adult participants. The
boxes represent the interquartile range (50%
of the values). The line across the box indi-
cates the median. The whiskers extend to the
95th and 5th percentiles.
tensive participants and non-diabetic non-hypertensive 20% (95% CI, 10 to 29%) of diabetics with a GFR less
than 30 mL/min/1.73 m2 demonstrated no albuminuria.participants), for all age groups, the prevalence of albu-
minuria increased in a step-wise fashion with a decline Similarly, 43% (95% CI, 30 to 56%) of non-diabetic
hypertensives with a GFR less than 30 mL/min/1.73 m2in GFR. However, as demonstrated in the Venn dia-
grams, it was clear that these screening tests were identi- demonstrated no albuminuria. Compared with other age
groups, renal insufficiency without albuminuria was leastfying different segments of the population. For example,
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Table 3. Prevalence of microalbuminuria and macroalbuminuria by age, and strata of renal insufficiency
Age
20–39 40–59 60–79 80 Total 95% CI
Whole population
Creatinine 177 men, 146 women (GFR 30)
Number 10 16 80 53 159
Microalbuminuria 11.4% 74.6% 25.0% 52.2% 37.4% 26.3–48.5%
Macroalbuminuria 77.0% 19.2% 18.6% 28.0% 26.0% 17.5–34.5%
Albuminuria 88.4% 93.8% 43.6% 80.2% 63.4% 53.6–73.2%
Creatinine 137–177 men, 104–146 women (GFR 30–60)
Number 139 202 537 255 1133
Microalbuminuria 15.7% 9.5% 23.9% 30.7% 20.0% 17.1–23.0%
Macroalbuminuria 1.4% 2.4% 4.2% 3.5% 3.3% 2.4–4.1%
Albuminuria 17.3% 11.9% 28.1% 34.2% 23.3% 20.1–26.4%
Creatinine 137 men, 104 women (GFR 60)
Number 5850 3792 2985 703 13330
Microalbuminuria 5.0% 6.6% 13.6% 25.0% 7.4% 6.7–8.0%
Macroalbuminuria 0.3% 0.8% 1.2% 3.3% 0.7% 0.5–0.9%
Albuminuria 5.3% 7.4% 14.8% 28.3% 8.1% 7.3–8.8%
Diabetic population
Creatinine 177 men, 146 women (GFR 30)
Number 2 6 32 14 54
Microalbuminuria 81.4% 17.5% 44.8% 36.2% 14.7–57.6%
Macroalbuminuria 18.6% 48.3% 40.7% 44.2% 23.5–64.9%
Albuminuria 100% 65.8% 85.5% 80.4% 71.0–89.7%
Creatinine 137–177 men, 104–146 women (GFR 30–60)
Number 7 21 112 39 179
Microalbuminuria 62.3% 31.7% 44.4% 35.8% 42.6% 33.6–51.7%
Macroalbuminuria 0% 9.6% 8.3% 8.2% 8.1% 3.5–12.8%
Albuminuria 62.3% 41.3% 52.7% 44.0% 50.7% 42.2–59.3%
Creatinine 137 men, 104 women (GFR 60)
Number 129 316 438 76 959
Microalbuminuria 19.2% 22.1% 31.2% 34.6% 25.5% 21.5–29.4%
Macroalbuminuria 1.9% 5.8% 3.3% 9.3% 4.3% 2.6–6.0%
Albuminuria 21.1% 27.9% 34.5% 43.9% 29.8% 25.6–34.0%
Non-diabetic hypertensive population
Creatinine 177 men, 146 women (GFR 30)
Number 5 9 41 36 91
Microalbuminuria 31.8% 66.6% 28.2% 56.2% 40.2% 27.5–52.9%
Macroalbuminuria 61.7% 21.0% 8.3% 24.3% 16.6% 8.6–24.6%
Albuminuria 93.5% 87.6% 36.5% 80.5% 56.8% 44.0–69.6%
Creatinine 137–177 men, 104–146 women (GFR 30–60)
Number 33 79 326 166 604
Microalbuminuria 11.1% 17.5% 23.7% 32.5% 23.4% 18.9–27.8%
Macroalbuminuria 5.4% 5.4% 4.3% 2.9% 4.3% 2.6–6.0%
Albuminuria 16.5% 22.9% 28.0% 35.4% 27.7% 23.1–32.4%
Creatinine 137 men, 104 women (GFR 60)
Number 827 1218 1507 439 3991
Microalbuminuria 4.7% 9.4% 15.9% 28.2% 11.2% 10.0–12.3%
Macroalbuminuria 0.5% 1.3% 1.0% 3.8% 1.1% 0.7–1.6%
Albuminuria 5.2% 10.7% 16.9% 32.0% 12.3% 11.1–13.6%
Non-diabetic non-hypertensive population
Creatinine 177 men, 146 women (GFR 30)
Number 3 1 7 3 14
Microalbuminuria 19.7%
Macroalbuminuria 10.0%
Albuminuria 29.7% 52.9% 16.2–89.6%
Creatinine 137–177 men, 104–146 women (GFR 30–60)
Number 99 100 96 47 342
Microalbuminuria 15.3% 3.2% 7.2% 18.1% 8.5% 4.6–12.5%
Macroalbuminuria 0.4% 0% 0.2% 2.5% 0.3% 0.0–0.7%
Albuminuria 15.7% 3.2% 7.4% 20.6% 8.8% 4.8–12.8%
Creatinine 137 men, 104 women (GFR 60)
Number 4791 2231 1024 183 8229
Microalbuminuria 4.8% 4.0% 5.3% 14.1% 4.7% 4.1–5.2%
Macroalbuminuria 0.2% 0.2% 0.9% 0% 0.3% 0.1–0.4%
Albuminuria 5.0% 4.2% 6.2% 14.1% 4.9% 4.4–5.5%
Weighted analysis of 14,622 survey participants. The number of participants refers to the crude, unweighted number, and groups with less than 5 persons were
not analyzed. Serum creatinine is in mol/L; GFR is glomerular filtration rate in mL/min/1.73 m2.
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Fig. 2. Venn diagrams for screening of serum creatinine and random urine albumin to creatinine ratio measured on a single occasion in the adult
whole (A), diabetic (B), non-diabetic (C ), and non-diabetic non-hypertensive (D) populations.
pronounced in younger adults and most pronounced in 20- to 39-year-old age group, one would need to screen
the age group of 60- to 79-years-old where 34% (95% 18 (95% CI, 16 to 21) members of the general population,
CI, 15 to 53%) of diabetics, and 64% (95% CI, 43 to 4 (95% CI, 3 to 8) people with diabetes, 17 (95% CI, 13
84%) of non-diabetic hypertensives with a GFR less than to 27) people with hypertension who were not diabetic,
30 mL/min/1.73 m2 demonstrated no albuminuria. or 19 (95% CI, 17 to 22) people who were not diabetic
or hypertensive, to identify one individual with micro-
Number needed to screen to identify one person albuminuria (regardless of GFR). Findings of renal insuf-
with findings ficiency and albuminuria become more prevalent with
For the purposes of guiding future screening initia- older age in the whole, diabetic, non-diabetic hyperten-
tives, the prevalence of various states of albuminuria and sive and non-diabetic non-hypertensive populations, and
renal insufficiency in four different target groups (the the NNS is lower.
whole population, diabetics, non-diabetic hypertensives
and non-diabetic non-hypertensives) for four different
DISCUSSIONage categories (20 to 39, 40 to 59, 60 to 79 and 80 years of
A number of screening criteria applied either at aage and over) is presented in Table 4. These prevalence
single time or serially, could be used to identify individu-estimates are presented as the number of persons one
als at high risk of ESRD. Our study focused on two suchwould need to screen [number-needed-to-screen (NNS)]
criteria measured on a single occasion (albuminuria andto identify one participant with the constellation of find-
renal insufficiency), and estimated the prevalence of theseings specified in the left-hand column of this table. For
conditions in the U.S. non-institutionalized population.example, reading across the first row of Table 4, without
Based on the methods described in this report, 16 adultsscreening for serum creatinine concentration, and using
a spot collection for albumin-to-creatinine ratio in the (95% CI, 14 to 18) need to be screened to identify one
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individual with a serum creatinine corresponding to a lent non-diabetic hypertensives may demonstrate a se-
rum creatinine corresponding to a GFR less than 60 mL/GFR less than 60 mL/min/1.73 m2, and 174 (95% CI, 137
to 236) for a GFR less than 30 mL/min/1.73 m2. Eleven min/1.73 m2, and 1 in every 75 (95% CI, 59 to 103) may
demonstrate a level corresponding to a GFR less than(95% CI, 10 to 12) adults need to be screened to identify
one individual with albuminuria, and this number de- 30 mL/min/1.73 m2.
Strengths of the presented data include utilization ofcreases in certain subgroups; 3 (95% CI, 3 to 3) diabetics,
7 (95% CI, 6 to 8) non-diabetic hypertensives, and 6 a sample representative of the U.S non-institutionalized
population, where careful standardized methods of data(95% CI, 5 to 6) persons over 60 years of age need to
be screened to identify one person with albuminuria. collection were employed. However, limitations of the
presented data should be recognized. Measurements ofOverall these data are important, because they describe
the frequency with which renal insufficiency and albu- serum creatinine and albuminuria are subject to consid-
erable patient and laboratory variability, and it remainsminuria are found in a single community screening mea-
surement. Albuminuria on a random spot urine albumin- unclear to what extent results from tests assessed on a
single occasion identify important pathology. For exam-to-creatinine ratio is prevalent, particularly in diabetics,
non-diabetic hypertensives, and older individuals. ple, a proportion of these abnormalities may not persist
with subsequent testing, and for this reason the Ameri-It was evident that screening tests of albuminuria and
renal insufficiency measured on a single occasion identi- can Diabetes Association recommends at least two of
three random spot urine collections done in a three tofied different segments of the population (Fig. 2). Ap-
proximately 1 in every 25 persons with albuminuria dem- six month period demonstrate elevated levels before la-
beling a patient with microalbuminuria [4] (althoughonstrated a GFR less than 30 mL/min/1.73 m2. Similarly,
two out of every three persons with a GFR less than 30 recommended strategies to overcome diagnostic uncer-
tainty by repeated testing may reduce adherence in pri-mL/min/1.73 m2 demonstrated albuminuria. Non-albu-
minuric renal insufficiency (1 out of every 3 persons with mary care settings [40], and may not improve diagnostic
accuracy [41]). Microalbuminuria as assessed on a singleGFR less than 30 mL/min/1.73 m2) was most evident in
the ages of 60 to 79, and least evident in younger adults. occasion is common in children [29] and younger adults,
and the prognostic importance of albuminuria in theseWe hypothesize that certain risk factors for non-albu-
minuric renal insufficiency (such as senescence, renal screening groups remains to be clarified. These data uti-
lize cut-off points of urine albumin-to-creatinine ratiosvascular disease, hypertension, and specific medication
use) have greatest effects in older adults. A similar find- to define overt proteinuria, and serve as a surrogate mea-
sure for future strategies that may utilize dipstick pro-ing was also reported in Heart Outcomes and Prevention
Evaluation (HOPE) study, where two thirds of older teinuria testing. Individuals with hematuria and pro-
teinuria, a small segment of the population at risk ofpatients with renal insufficiency demonstrated no albu-
minuria [39] (individuals with a serum creatinine greater progressive renal disease [42], were excluded from this
analysis. The primary definitions used here to definethan 200 mol/L or dipstick proteinuria greater than 1
were not participants of this study). These results confirm albuminuria and renal insufficiency, which we have gen-
eralized to the non-institutionalized U.S. population,that comprehensive screening initiatives may need to
integrate a number of different criteria to identify indi- were validated only in specific populations against a con-
current gold standard test (such as inulin clearance orviduals at risk of ESRD, and that different criteria may
be valuable in different age groups or at-risk populations. 24 hour albuminuria). Some of the prevalence estimates
for albuminuria and renal insufficiency were based on aThe numbers-needed-to-screen to detect albuminuria
and renal insufficiency for four different target groups limited number of observations, and as noted in Table 4
these results should be interpreted with caution. Finally,(the whole population, diabetics, non-diabetic hyperten-
sives, and non-diabetic non-hypertensives) and four dif- from a screening perspective, it is most clinically useful
to characterize the prevalence of individuals with testferent age categories (20 to 39, 40 to 59, 60 to 79 and 80
years of age and over) are presented in Table 4. We results of interest, who at the time of screening are not
receiving effective interventions to reduce the risk ofhave identified the number of persons who would need
to be screened to identify one person with a screening adverse clinical events. At the time of NHANES III, the
majority of interventions that reduce the risk of progres-strategy specified in the left-hand column. These data
guide future population screening initiatives, and high- sion of renal disease had not been proven. Consequently,
identifying the prevalence of participants in the study,light the importance of knowledge of prevalence in pre-
dicting the range of possible values for the usefulness of whose management would have been altered by renal
insufficiency and/or albuminuria identification, wouldscreening. For example, hypertension clinical practice
guidelines recommend a serum creatinine measurement have been of limited utility.
Future evidence-based screening initiatives should ex-at the time of diagnosis [7, 8]. These data would predict
that approximately 1 in every 9 (95% CI, 8 to 10) preva- tend these findings, and aim at quantifying the number
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Table 4. The anticipated results of screening using different combinations of criteria with respect to a single measurement of serum creatinine
and/or urine albumin-to-creatinine ratio
Number of persons needed to be screened to identify one screening finding or
combination of findings
Non-diabetic Non-diabetic
Screening strategy Whole population Diabetic population hypertensive population non-hypertensive population
Ages 20–39
Albuminuria 18 (16–21) 4 (3–8) 17 (13–27) 19 (17–22)
Macroalbuminuria 256 (175–478) 28 (15–198)a 122 (73–368) 397 (225–1724)
Cr 137 men, 104 women (GFR 60) 54 (44–69) 22 (11–1087)a 35 (25–60) 60 (47–85)
Cr 177 men, 146 women (GFR 30) 935 (532–3704)a 53 (21)ab 365 (233–833)a 2381 (855–)ab
Cr  137 men, 104 women (GFR 60)
or albuminuria 14 (13–16) 4 (3–7) 13 (10–16) 15 (13–17)
Cr 137 men, 104 women (GFR 60)
and albuminuria 253 (179–435) 29 (13–)ab 147 (99–288) 350 (208–1087)
Cr 137 men, 104 women (GFR 60)
and macroalbuminuria 935 (526–4000)a 56 (21–)ab 326 (177–2000)a 2564 (917–)ab
Cr 177 men, 146 women (GFR 30)
or macroalbuminuria 240 (165–441) 27 (15–173)a 108 (68–259) 383 (219–1515)
Cr 177 men, 146 women (GFR 30)
and albuminuria 1053 (575–6250)a 56 (21–)ab 389 (249–893)a 3030 (971–)ab
Cr 177 men, 146 women (GFR 30)
and macroalbuminuria 1205 (613–33333)a 56 (21–)ab 592 (290–)ab 3030 (971–)ab
Ages 40–59
Albuminuria 13 (12–14) 3 (3–4) 9 (8 –10) 24 (20–32)
Macroalbuminuria 106 (75–182) 16 (10–39) 63 (42–124) 571 (258–)ab
Cr 137 men, 104 women (GFR 60) 21 (19–25) 20 (13–43) 17 (14–22) 24 (21–30)
Cr 177 men, 146 women (GFR 30) 407 (229–1786) 49 (23–)ab 245 (117–)ab 8333 (2941–)ab
Cr 137 men, 104 women (GFR 60)
or albuminuria 9 (8–9) 3 (3–4) 6 (6–7) 12 (11–15)
Cr 137 men, 104 women (GFR 60)
and albuminuria 131 (99–196) 31 (17–156) 63 (43–118) 699 (379–4545)
Cr 137 men, 104 women (GFR 60)
and macroalbuminuria 649 (450–1163) 151 (78–)ab 265 (176–526)a ( )b
Cr 177 men, 146 women (GFR 30)
or macroalbuminuria 87 (64–138) 13 (8–30) 52 (36–96) 535 (250–)ab
Cr 177 men, 146 women (GFR 30)
and albuminuria 433 (245–1852) 49 (23–)ab 280 (136–)ab 8333 (2941–)ab
Cr 177 men, 146 women (GFR 30)
and macroalbuminuria 2128 (1163–11111)a 266 (119–)ab 1163 (568–)ab ( )b
Ages 60–79
Albuminuria 6 (5–6) 3 (2–3) 5 (5–6) 16 (13–20)
Macroalbuminuria 52 (40–75) 17 (11–33) 58 (41–98) 117 (65–588)a
Cr 137 men, 104 women (GFR 60) 6 (6–7) 4 (3–4) 5 (5–6) 11 (9–14)
Cr 177 men, 146 women (GFR 30) 61 (50–79) 29 (19–54) 47 (36–68) 395 (216–2381)a
Cr 137 men, 104 women (GFR 60)
or albuminuria 4 (3–4) 2 (2–2) 3 (3–3) 7 (6–8)
Cr 137 men, 104 women (GFR 60)
and albuminuria 21 (18–25) 7 (6–9) 19 (15–24) 138 (85–368)
Cr 137 men, 104 women (GFR 60)
and macroalbuminuria 110 (77–193) 28 (17–77) 113 (73–257) 2273 (926–)ab
Cr 177 men, 146 women (GFR 30)
or macroalbuminuria 31 (26–38) 13 (9–21) 27 (22–35) 92 (55–279)
Cr 177 men, 146 women (GFR 30)
and albuminuria 141 (98–251) 43 (26–138) 129 (78–379) 1333 (602–)ab
Cr 177 men, 146 women (GFR 30)
and macroalbuminuria 330 (200–935) 59 (32–362) 568 (262–)ab 4000 (1370–)ab
Ages 80 and over
Albuminuria 3 (3–3) 2 (2–3) 3 (2–3) 6 (5–10)
Macroalbuminuria 21 (16–32) 8 (5–30) 21 (15–34) 184 (64–)ab
Cr 137 men, 104 women (GFR 60) 3 (3–3) 2 (2–3) 3 (3–3) 5 (4–6)
Cr 177 men, 146 women (GFR 30) 19 (15–26) 9 (6–21) 17 (13–26) 189 (74–)ab
Cr 137 men, 104 women (GFR 60)
or albuminuria 2 (2–2) 1 (1–2) 2 (2–2) 3 (3–4)
Cr 137 men, 104 women (GFR 60)
and albuminuria 7 (6–9) 4 (3–7) 7 (6–8) 23 (15–57)
Cr 137 men, 104 women (GFR 60)
and macroalbuminuria 40 (29–65) 14 (8–70) 44 (30–78) 184 (64–)ab
Cr 177 men, 146 women (GFR 30)
or macroalbuminuria 12 (10–15) 5 (3–11) 11 (9–14) 96 (42–)ab
(Continued)
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Table 4. (Continued)
Number of persons needed to be screened to identify one screening finding or
combination of findings
Non-diabetic Non-diabetic
Screening strategy Whole population Diabetic population hypertensive population non-hypertensive population
Cr 177 men, 146 women (GFR 30)
and albuminuria 24 (18–35) 10 (6–27) 21 (15–35) 1786 (629–)ab
Cr 177 men, 146 women (GFR 30)
and macroalbuminuria 68 (45–134) 22 (10–)ab 70 (43–188) 3571 (1250–)ab
Ages 20 and over
Albuminuria 11 (10–12) 3 (3–3) 7 (6–8) 20 (18–22)
Macroalbuminuria 102 (84–132) 16 (12–26) 60 (48–80) 345 (222–781)
Cr 137 men, 104 women (GFR 60) 16 (14–18) 6 (5–8) 9 (8–10) 30 (26–36)
Cr 177 men, 146 women (GFR 30) 174 (137–236) 31 (21–59) 75 (59–103) 1724 (909–20000)
Cr 137 men, 104 women (GFR 60)
or albuminuria 7 (7–8) 2 (2–3) 4 (4–5) 12 (11–14)
Cr 137 men, 104 women (GFR 60)
and albuminuria 59 (49–74) 11 (9–14) 28 (23–35) 313 (212–588)
Cr 137 men, 104 women (GFR 60)
and macroalbuminuria 297 (228–426) 40 (26–88) 151 (112–231) 3125 (1370–)ab
Cr 177 men, 146 women (GFR 30)
or macroalbuminuria 71 (59–89) 13 (10–19) 36 (31–44) 307 (204–621)
Cr 177 men, 146 women (GFR 30)
and albuminuria 274 (199–439) 39 (26–79) 133 (93–231) 3226 (1429–)ab
Cr 177 men, 146 women (GFR 30)
and macroalbuminuria 667 (469–1149) 71 (42–219) 455 (292–1031) 4545 (1631–)ab
Prevalence estimates are presented as the number of persons one would need to screen to identify one participant with the constellation of findings specified in
the left-hand column of the table.
For example, if screening the diabetic population ages 20 to 39 with a urine albumin-to-creatinine ratio alone, 4 persons would need to be screened to identify
one person with albuminuria. Point estimates are provided with 95% confidence intervals. Albuminuria describes the presence of either microalbuminuria or
macroalbuminuria. Serum creatinine is in mol/L; GFR is glomerular filtration rate in mL/min/1.73 m2.
a Estimate was based on 10 or less unweighted participants demonstrating the finding, and as a result should be interpreted with caution
b An estimate was not possible because of the limited number of participants demonstrating finding
of persons that need to be screened with serum creatinine a useful strategy. The importance of screening and in-
tervening for renal disease in the larger setting of screen-and/or random urine albumin-to-creatinine ratio to pre-
vent one person developing ESRD. This estimate is much ing and intervening for diabetes [47], hypertension and
prevention of cardiovascular disease, remains to be clari-larger in magnitude than the numbers-needed-to-screen
to identify a risk factor of interest. At this time, insuffi- fied. Using screening tests of proteinuria and renal insuf-
ficiency to prevent multiple outcomes of interest (such ascient data on a number of intermediate steps between
identification of a risk factor and prevention of ESRD ESRD, renal insufficiency complications, cardiovascular
events or mortality) will improve the efficacy of screen-are available to permit reliable numeric estimations of
the numbers-needed-to-screen to prevent adverse clini- ing, recognizing that the presence of albuminuria may
have important predictive validity for future cardiovas-cal events. A better understanding of community ESRD
incidence, risk factor prevalence, existing intervention cular clinical events at cut-off levels below those stan-
dardized with concurrent gold standard tests [48]. Meth-use, and cumulative intervention effectiveness will guide
this estimate. Furthermore, from a health services per- ods of valuing clinical events (such as distinguishing
ESRD in younger vs. older persons) may require otherspective, many other issues need to be addressed to
achieve effective screening strategies. The economics of statistical measures (such as quality of life years lost) to
be considered in the assessment of the potential valuescreening, intervention application, and acquired ESRD
need to be understood to develop comprehensive, cost- of screening to society.
In summary, these data demonstrate that a finding ofeffective strategies [43, 44]. The ethics of screening, in-
cluding the harm associated with labeling [45], and down- albuminuria on a single random spot urine albumin-to-
creatinine ratio is prevalent, particularly in diabetics,stream effects of false-positive results (such as patient
anxiety and increased health care utilization) require non-diabetic hypertensives, and older individuals. When
considered together, single observations of albuminuriaconsideration. Methods of screening delivery, such as
patient-, primary care physician-, or laboratory-initiated and renal insufficiency identify different segments of the
population. To be comprehensive, screening initiativesscreening should be examined. The identification of indi-
viduals at risk, by using pre-existing data in laboratory may need to integrate a number of different criteria to
identify individuals at risk of ESRD. The prevalencesurveillance programs [46], is opportunistic and may be
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